



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Ming-Hui Duan
✉ mhduan@sina.com

†These authors have contributed equally to
this work

RECEIVED 04 June 2025

ACCEPTED 06 June 2025

PUBLISHED 19 June 2025

CITATION

Chang L, Li W-X, Cai H, Li J and Duan M-H
(2025) Correction: Efficacy and safety of
pegylated interferon in the treatment of
JAK2^{V617F}-positive polycythemia vera
with a dose de-escalation strategy:
a single-center retrospective study.
Front. Oncol. 15:1641150.
doi: 10.3389/fonc.2025.1641150

COPYRIGHT

© 2025 Chang, Li, Cai, Li and Duan. This is an
open-access article distributed under the terms
of the [Creative Commons Attribution License](#)
(CC BY). The use, distribution or reproduction
in other forums is permitted, provided the
original author(s) and the copyright owner(s)
are credited and that the original publication
in this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Correction: Efficacy and safety of pegylated interferon in the treatment of JAK2^{V617F}-positive polycythemia vera with a dose de-escalation strategy: a single-center retrospective study

Long Chang^{1,2†}, Wen-Xin Li^{1,2†}, Hao Cai^{1,2}, Jian Li^{1,2}
and Ming-Hui Duan^{1,2*}

¹Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ²State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Beijing, China

KEYWORDS

polycythemia vera, pegylated interferon, JAK2v617F mutation, dose de-escalation strategy, hematological and molecular response

A Correction on

Efficacy and safety of pegylated interferon in the treatment of JAK2^{V617F}-positive polycythemia vera with a dose de-escalation strategy: a single-center retrospective study

By Chang L, Li W-X, Cai H, Li J and Duan M-H (2025). *Front. Oncol.* 15:1586839. doi: 10.3389/fonc.2025.1586839

In the published article, there was an error in the **Funding** statement. “The funder National High Level Hospital Clinical Research Funding 2022-PUMCH-B-047 to Ming-hui Duan” was erroneously omitted. The correct **Funding** statement appears below.

“This study was supported by the National High Level Hospital Clinical Research Funding 2022-PUMCH-B-047 to Ming-hui Duan. This study also received funding from Xiamen Amoytop Biotech Co., Ltd. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.